Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map
Immune Response BioPharma, Inc.  TM     Copyright © 2010-2018

About Immune Response BioPharma, Inc. FAQ:

Immune Response BioPharma, IncTM is a Delaware corporation and is a leading vaccine development company that has its own proprietary drug pipeline under development and currently owns 100% of its drugs and vaccine treatments. Development of current drug pipeline along with timing and starting of projects will be at Immune Response BioPharma TM discretion. The King Patent U.S. 8,053,197 Issued & Granted to Immune Response BioPharma, Inc. Extends IP Coverage for Auto-Immune Disease Treatment & Vaccination Until 2027. IRBP is an FDA Orphan Pediatric Drug Maker with two FDA designated orphan pediatric vaccines Remune 
for HIV pediatric & NeuroVax for pediatric MS. 
 

 
Patent Coverage through 2027 with The King Patent U.S. Patent 8,053,197 Issued and Granted Ownership to Immune Response BioPharma, Inc. for Auto-Immune Diseases Proprietary FOXP3+ Expression Technology.
 
 
Dividends: The company plans to pay dividends and will begin paying regular dividends in the future based upon cash-flow and earnings.
 
 
Mission Statement:  To Become the World Leader in Saving Lives & Vaccine Technology.
 
 


AIRBP is a new entity  and the new company has no legal liability in regards to the old company, as well restarting & reorganizing the company and development of the REMUNE & NeuroVax technology is at the discretion of Immune Response BioPharma, Inc TM in order to advance science and save lives. 
 
 
Restarting the company and continuing the work of Remune & NeuroVax is at the discretion of IRBP, as it is important to bring novel drugs and vaccines to the marketplace to save lives.
 
Restarting the clinical projects such as Remune and Neurovax will be at the discretion of Immune Response BioPharma, Inc. TM.
 
The name of the company Immune Response BioPharma, Inc. and its blue logo represent a new and fresh start for the the future.
 
All clinical pipeline drugs are eligible for 5 years exclusivity under the Hatch Waxman Act and will seek orphan designation of 7 years exclusivity. The King Patent U.S. 8,053,197 Extends IP Coverage until 2027 for Auto-Immune Disease Treatment & Vaccination Methods.
 
Intellectual Property: of Immune Response BioPharma, Inc.TM is sole property of the company and its shareholders.
All Trademarks and IP in current use by current logo are property of Immune Response BioPharma, Inc. TM and copyright protected under Federal Law Copyright © 2010-2018.
 
 
Patent Coverage: Through 2027 with U.S. Patent 8,053,197 Granted & Issued Ownership to Immune Response BioPharma, Inc. for Auto-Immune Diseases Proprietary FOXP3+ Expression Technology.
 
 
Immune Response BioPharma TM  has no legal obligation, liability, nor legal responsibility to anyone not affiliated with the company.

Social Responsibility:  Socially responsible activities of saving lives and helping sick and ill patients is paramount to the mission and goals of Immune Response BioPharma TM and thus will take appropriate action to develop life saving drugs and therapies to benefit society. IRBP prides itself on being ethically responsible in its clinical studies focused on patients & their therapeutic successes in & out of the clinic. 
 
 

 

 

Q: What is IMMUNE RESPONSE BIOPHARMA, Inc.?

A: The Company IRBP was started to develop novel drugs to combat life threatening diseases. IRBP has filed for incorporation and is now incorporated in the state of Delaware as of June 17th 2011.
 
 

CERTIFICATE OF INCORPORATION

State of Delaware

Secretary of State

Division of Corporations

Delivered 01:28 PM 06/20/2011

FILED 12:27 PM 06/20/2011

SRV 110739145 - 4999105 FILE

FIRST: The name of this corporation shall be: Immune Response BioPharma, Inc.

SECOND: Its registered office in the State of Delaware is to be located at 2711 Centerville

Road, Suite 400, Wilmington, County of New Castle, Delaware, 19808. The name of its registered

agent at such address is Corporate Agents, Inc.

THIRD: The purpose or purposes of the corporation shall be:

To engage in any lawful act or activity for which corporations may be

organized under the General Corporation Law of Delaware.

FOURTH: The total number of shares of stock, which this corporation is authorized to issue,

is One Thousand Five Hundred (1,500) shares of common stock without par value.

FIFTH: The name and address of the incorporator is as follows:

Corporate Agents, Inc.

2711 Centerville Road

Suite 400

Wilmington, Delaware 19808

SIXTH: The Board of Directors shall have the power to adopt, amend or repeal the by-laws.

SEVENTH: No director shall be personally liable to the Corporation or its stockholders for

monetary damages for any breach of fiduciary duty by such director as a director. Notwithstanding

the foregoing sentence, a director shall be liable to the extent provided by applicable law, (i) for

breach of the director's duty of loyalty to the Corporation or its stockholders, (ii) for acts or

omissions not in good faith or which involve intentional misconduct or a knowing violation of law,

(iii) pursuant to Section 174 of the Delaware General Corporation Law or (iv) for any transaction

from which the director derived an improper personal benefit. No amendment to or repeal of this

Article Seventh shall apply to or have any effect on the liability or alleged liability of any director

of the Corporation for or with respect to any acts or omissions of such director occurring prior to

such amendment.

IN WITNESS WHEREOF, the undersigned, being the incorporator herein before named, has

executed signed and acknowledged this certificate of incorporation this 20th day of June, 2011.

Corporate Agents, Inc., Incorporator

By: /s/ Margaret Rosado

Name: Margaret Rosado

Assistant Secretary

DE BC D-:CERTIFICATE OF INCORPORATION - SHORT SPECIMEN 09/00-1 (DESHORT)




Immune Response BioPharma, Inc.TM
Copyright © 2010-2018       www.immuneresponse.net
            All Rights Reserved